Mohammad Alashqar/LinkedIn
May 20, 2026, 12:42
Mohammad Alashqar: Cost-Effectiveness of Fitusiran Prophylaxis in Severe Hemophilia A Without Inhibitors
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
”Proud to present poster N 3044 at ISPOR – The Professional Society for Health Economics and Outcomes Research 2026 on the ‘cost-effectiveness of fitusiran prophylaxis versus FVIII prophylaxis or on-demand therapy for patients with severe hemophilia A without inhibitors.’
Grateful to represent The Ohio State University College of Pharmacy and contribute to discussions advancing HEOR, value assessment, and evidence-based care.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026